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Abstract
Objectives: Thyroid hormones play an important role in the maintenance of pregnancy. 
Their derivates, endogenous amines, act via binding to the trace amine-associated 
receptor (TAAR1). The aim of our study was to analyse the regulation of TAAR1,  
serine/threonine kinase (pGSK3β) and ornithine decarboxylase (ODC) in placentas 
of healthy pregnancies, spontaneous (SM) and recurrent miscarriages (RM) and to 
investigate the influence of thyroid hormone derivates on TAAR1 expression in 
trophoblast model cells in vitro.
Methods: Patients with SM (n = 15) and RM (n = 15) were compared with patients with 
healthy pregnancies (n = 15) (pregnancy weeks 7–13 each). Immunohistochemistry was 
applied to analyse placental TAAR1, pGSK3β and ODC expression. Protein expression 
of the receptors after stimulation with T3, T1AM and RO5203548 in BeWo trophoblast 
model cells was determined via Western blot. Double-immunofluorescence was used to 
determine placental expression of TAAR1 and ODC.
Results: Levels of TAAR1, pGSK3β and ODC were higher in placentas of RM in comparison 
to healthy controls. Stimulation of BeWo cells with T3, T1AM and RO5203548 significantly 
increased TAAR1 expression. ODC expression in BeWo cells was upregulated through T3. 
Via double-immunofluorescence, TAAR1 and ODC-positive EVT could be detected.
Conclusions: Upregulation of placental TAAR1 may indicate an increased 
decarboxylation of thyroid hormones in miscarriages. Patients with RM may have a lack 
of T3 through an enhanced transformation of T3 into T1AM induced by the ODC. Future 
investigations could be carried out to analyse what role a prophylactic T3 substitution 
plays for patients.
Introduction
Thyroid disorders such as hypothyroidism and 
hyperthyroidism are associated with increased miscarriage 
and stillbirth rates (1). Untreated hypothyroidism can 
result in a twofold increase of miscarriages; therefore, the 
maintenance of an euthyroid state is crucial for a healthy 
pregnancy (2). Thyroid hormones, which bind to the 
thyroid hormone receptor (THR), play an important role 
during trophoblast differentiation and the development 
of the foetal nervous system (3). THR belongs to the 
nuclear receptor superfamily, and it is involved in various 
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physiological processes (4). In a former study, we were able 
to show that mRNA and protein expression of the THR 
isoforms THRα1, THRα2, THRβ1 and THRβ2 are reduced 
in spontaneous and recurrent miscarriages (RM) (5). 
The majority of THR seems to be expressed by decidual 
stromal cells (5).
Degradation of thyroid hormones results in the 
formation of trace amines (TAs), also referred to as 
thyronamines or endogenous amines (6). Transformation 
of thyroid hormones into TAs is conducted by the enzyme 
ornithine decarboxylase (ODC) through a deiodisation 
and a decarboxylation process (7). Thyronamines (3-T1AM, 
T0AM) are endogenous compounds, which can possibly be 
derived from l-thyroxine (T4) (7). Decarboxylated thyroid 
hormones act through rapid actions like rapid lowering of 
body temperature and heart rate, while classical thyroid 
hormones act epigenetically (8). Ornithine decarboxylase 
(ODC) is a rate-limiting enzyme for the biosynthesis of 
polyamines, and it is responsible for the decarboxylation 
of thyroid hormones (9, 10). Changes in the brain 
ODC/polyamine system can have an influence on the 
development of catecholaminergic nerve pathways (11). 
Bulgaroni and colleagues found that ODC upregulation 
may be linked to cytotrophoblast proliferation and 
placental repair in compensation to injuries induced by 
organophosphate pesticides (12).
Thyroid hormone derivates function by binding to 
the G-protein-coupled receptor trace amine-associated 
receptor 1 (TAAR1) (8). TAAR1 was first described in 2001 
by Borowsky and coworkers (13). Upon activation of 
adenylcyclase, TAAR1 induces a rise of the intracellular 
cAMP level (13, 14). TAAR1 is expressed by the placenta, 
brain, spinal cord, stomach, pancreatic β-cells and immune 
cells like macrophages, leukocytes and dendritic cells (15, 
16, 17). Different compounds, including dopaminergic, 
adrenergic and serotonergic classes and a wide spectrum of 
agonists, such as trace amines, common biogenic amines, 
amphetamine-like stimulants and 3-iodothyronamine 
can activate TAAR1 (18, 19, 20). The only known TAAR1 
antagonist to date is RO5212773 (EPPTB) (21).
TAAR1 has so far been investigated in the field of 
neuroscience whereby it could be shown that TAAR1 is 
able to modulate the serotonergic and dopaminergic 
system in the brain (15). As TAAR1 is a negative regulator 
of dopamine transmission, TAAR1 and its agonists as well 
as antagonists represent a target for psychiatric disorders 
like Parkinson’s disease, depression and schizophrenia 
(15). Stimulation of TAAR1 can furthermore have a 
beneficial effect on glucose and obesity control in mice 
with type 2 diabetes mellitus (22).
In a recent study, we analysed the regulation of 
TAAR1 in breast cancer tissue of primary breast cancer 
patients and identified that TAAR1 seems to be an 
independent predictor for breast cancer survival (23). 
TAAR1 overexpression (IRS ≥ 6) was associated with a 
significantly longer overall survival (OS) of breast cancer 
patients (P = 0.02) than reduced TAAR1 expression (IRS < 6) 
during a maximum follow-up of 14 years, demonstrating 
that TAAR1 has a favourable effect on OS of early breast 
cancer patients (23).
It is speculated that TAAR1 directly or indirectly 
interferes with the β-arrestin2/Akt/GSK3 pathway (24, 25). 
GSK3 is a serine/threonine protein kinase, and it is encoded 
by the two genes GSK3A and GSK3B (26). Besides cellular 
proliferation, migration, glucose regulation and apoptosis, 
the isoform GSK3β is a key enzyme in the wnt-signalling 
pathways (27). Those are a group of signal transduction 
pathways that play an important role in carcinogenesis and 
embryo development. The latter is controlled through cell 
proliferation and cell migration, and wnt pathways regulate 
pre-implantation, blastocyst implantation and uterine 
decidualisation (27). Wnt-signalling proteins participate 
in numerous developmental events during embryogenesis 
and differentiation of diverse reproductive tissues (28, 29).
A crosstalk between TAAR1 and dopamine D2L 
receptor (D2R) has formerly been described (6, 30, 31). 
Harmeier and colleagues found that the activation of 
the TAAR1-D2R complex negatively modulates GSK3β 
signalling in vitro and in vivo. D2R is a target receptor for 
various antipsychotic drugs, and TAAR1 can interact with 
D2R forming a functional heteromer (6, 32).
Aim of our study was to investigate the placental 
expression of TAAR1, GSK3β and ODC in healthy 
pregnancies and spontaneous as well as RM and to 
further analyse the crosstalk between these receptors. 
Additionally, the influence of TAAR1 ligands on the 
expression of TAAR1 in trophoblast model cells in vitro 
was assessed. As we assume that the processing of thyroid 
hormones through the ODC plays an important role 
during miscarriages, regulation of the ODC was a further 
component of the study.
Materials and methods
Tissue samples
Samples collected from spontaneous (SM, 15 cases) and 
RM, 15 cases) in the time period between 2011 and 2012 
were obtained from the archives of the Gynaecology 
and Obstetrics Department of the Ludwig-Maximilians-
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University Munich, Germany. Samples from elective 
terminations of pregnancy (ETP, 15 cases) collected in 
the same time period were provided by outpatients clinic 
in Munich. Tissue samples were attained by curettage 
without any prior pharmacological induction. In cases 
of miscarriages, curettages were performed within 
24 h after diagnosis. The average gestational age for 
ETP was 10.6 ± 2.1, for SM 10.1 ± 1.5  weeks and for RM 
10 ± 1.5 weeks. Hypothyroidism as well as hyperthyroidism 
and TPO antibody positivity was excluded in all women. 
History taking was comprehensive, aiming to exclude—
apart from common disorders—potential involvement of 
clotting disorders and autoimmune diseases, which are 
already known as aggravating factors for increased risk 
for miscarriages. In all samples, analysis of chromosomal 
abnormalities was performed. In this study, PowerPlex 
16HS multiple PCR system was used, which detects 
16 STR loci, with the limitation of this method in picking 
up chromosomal abnormalities at base pair level. Analyses 
were carried out for all samples including controls. DNA 
extraction and profiling were performed as described 
by Ziegelmüller and coworkers (33). The PCR products 
were also analysed as described (33). Additionally, in 
all samples, microbiology analysis excluded possible 
intra-uterine infection. All women had a normal first 
trimester vaginal swab.
Ethical approval and informed consent
All procedures that involved human participants 
were in accordance with the ethical standards of the 
institutional and/or national research committee and 
with the Helsinki declaration of 1964 and its later 
amendments or comparable ethical standards. The 
study was approved by the Local Ethics Committee 
of the Ludwig-Maximilians University of Munich, 
Germany, and was assigned the reference number 337-
06. Consent has been obtained from each patient or 
subject after full explanation of the purpose and nature 
of all procedures used.
Immunohistochemistry
After tissue preparation, tissue samples were fixed in 3.7% 
formalin and then embedded in paraffin. Formalin-fixed 
paraffin-embedded sections (3 µm) were deparaffinised 
in Roticlear (Carl Roth, Karlsruhe, Germany), blocked 
and rehydrated with 3% H2O2/methanol for 20 min. 
Rehydration of the slides was carried out by using an 
alcohol gradient up to distilled water. The slides were 
placed in a pressure cooker containing sodium citrate 
(pH = 6.0). A blocking solution was used (Polymer Kit, 
Zytomed Systems, Berlin, Germany) to prevent any 
non-specific binding of the primary antibodies. Tissue 
sections were then incubated with the primary antibodies 
for 16 h at 4°C (Table  1). Reactivity was detected 
by using the ZytoChem Plus HRP Polymer System 
(Mouse/Rabbit) (Zytomed Systems; catalogue-ID: 
POLHRP-100), in accordance with the manufacturer’s 
protocol. Staining was performed with DAB and 
counterstaining was performed with hemalaun. 
Appropriate positive controls (brain tissue for GSK3-β 
and breast cancer tissue (23) and intestinal tissue for 
TAAR1 (34)) and negative controls (negative control 
serum added on third trimester placenta) (Negative 
Control for Super Sensitive Rabbit Antibodies, Rabbit 
IgG, BioGenex, Fremont, USA) were included in each 
experiment (Supplementary Fig.  1, see section on 
supplementary data given at the end of this article). 
Positive and negative control experiments of TAAR1 
expression are shown in the Supplementary figure. Per 
slide, ten fields were examined by two independent 
observers with a Leitz Diaplan microscope (Leitz, 
Wetzlar, Germany) by applying the semi-quantitative 
immunoreactive score (IRS) (35). The IRS is calculated 
by multiplying the intensity of cell staining (0: none; 
1: weak; 2: moderate; 3: strong) with the percentage of 
positively stained cells (0: no staining; 1: <10% of the 
cells; 2: 11–50%; 3: 51–80%; 4: >80%).
The pattern of the immunochemical staining reaction 
was evaluated by two independent blinded observers 
including a gynaecological pathologist (D M). In one 
Table 1 Features of the antibodies used for staining.
 
Antibody
 
Incubation
 
Blocking solution
Blocking 
condition (min)
TAAR1, polyclonal (Rabbit IgG,  
Abcam)
1:800 in PBS 16 h at 4°C Reagent I (Polymer Kit, Zytomed 
Systems, Berlin, Germany)
15
Phosphorylated GSK3β, polyclonal 
(phosphoY216) (Rabbit IgG, Abcam)
1:100 in TBS 16 h at 4°C Reagent I (Polymer Kit, Zytomed 
Systems, Berlin, Germany)
5
ODC, monoclonal (Mouse IgG,  
Novus Biologicals)
1:4000 in PBS 16 h at 4°C Reagent I (Polymer Kit, Zytomed 
Systems, Berlin, Germany)
5 
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case, the evaluation of the two observers of the GSKβ 
expression differed. This case was re-evaluated by both 
observers together. After the re-evaluation, both observers 
achieved the same result.
Cell lines and cell stimulation
The choriocarcinoma cell lines BeWo (ECACC, Salisbury, 
UK) and JEG-3 (ATCC), which are useful models of 
human trophoblasts, were used for the study. The 
cells were cultured in DMEM (3.7 g/L NaHCO3, 4.5 g/L 
d-glucose, 1.028 g/L stable glutamine, and Na-Pyruvate; 
Biochrom, Berlin, Germany). 10% heat-inactivated 
FCS was added to the medium, and the solution was 
incubated at an atmospheric CO2 concentration of 
5% and at 37°C.
BeWo and JEG-3 cells were separately grown on 
sterile 12 multiwell slides at a density of 500,000 cells/mL 
DMEM with 10% foetal cow serum. After 4 h, medium was 
changed to pure DMEM. The cells were stimulated with 
0.01 nM or 0.1 nM triiodothyronine (T3) (Sigma T2877; 
Lot:106K1157V, Sigma-Aldrich), thyronamine (T0AM) 
(Fluka 80345, Lot: BCBL2185V, Buchs, Switzerland), 
3-Iodothyronamine (T1AM) (Cayman Chemical) and 
RO5203548 (Glixx Laboratories, Hopkinton, MA, USA) 
for 2 h (PCR samples) and 48 h (Immunocytochemistry 
and Western blot samples), respectively. Control 
cells were incubated without stimulants. As a control 
solvent, the following buffers were used: The stimulant 
T3 has been diluted in 1 M NaOH in DMEM (Dulbecco’s 
Modified Eagle Medium) and T1AM and RO5203548 
were diluted in DMSO (Dimethylsulfoxide).
Immunocytochemistry
After incubation, the Quadriperm slides were fixated in 
an ethanol/methanol solution for 15 min. Between each 
step, the slides were washed in PBS (Biochrom). Next, the 
primary antibody (anti-TAAR1) was applied for 16 h at 
4°C. Incubation with the secondary antibody (ZytoChem 
Plus HRP Polymer System (mouse/rabbit) Tytomed: Nr. 
POLHRP-100) for 30 min followed. Staining of the slides 
was carried out with 3-amino-9-ethylcarbazole plus (AEC 
plus; Dako) for 5–8 min, followed by counterstaining with 
hemalaun for 30 s and finally washing in tap water and 
cover-slipping of the slides.
Assessment of the slides was carried out with a Leitz 
Diaplan light microscope (Leitz) and a digital camera 
system (JVC, Yokohoma, Japan) by two independent 
observers. For each slide, six visual fields were examined 
at a magnification of ×10 and  25. Per field, the cells were 
counted and assigned to three groups (negative, low, 
medium/strong staining).
TaqMan-real-time PCR
RNA of stimulated and control JEG-3 and BeWo cells was 
isolated using the NucleoSpinRNAII (Macherey-Nagel, 
Düren, Germany). Quantification and evaluation of 
RNA samples was carried out with the NanoPhotometer 
(Implen, Munich, Germany).
Reverse transcription was performed using the 
High-Capacity cDNA reverse transcription kit (Applied 
Biosystems) with a temperature protocol of 25°C for 
10 min, 37°C for 2 h, 85°C for 5 s and hold at 4°C.
The PCR was performed in 96-well reaction plates 
holding a volume of 20 µL. Each well contained 1 µL 
TaqMan Gene Expression Assay 20× (Applied Biosystems), 
10 µL TaqMan Universal PCR Master Mix 2× (Applied 
Biosystems), 8 µL H2O (DEPC treated DI water, Sigma) 
and 1 µL sample. For the PCR assay, ABI PRISM 7500 
Fast (Applied Biosystems) was used with thermal cycling 
conditions of 20 s at 95°C, 40 cycles of amplification 
with 3 s at 95°C and 30 s at 60°C. For quantification of 
the expression, the 2−ΔΔCT method was used by applying 
β-actin as the housekeeping gene. Each experiment was 
validated three times.
Western blot
Stimulated and control cell samples were lysed for 
30 min with 200 µL buffer solution consisting of a 1:100 
dilution of protease inhibitor (Sigma-Aldrich) in RIPA 
buffer (Radioimmunoprecipitation assay buffer, Sigma-
Aldrich). The lysate was centrifuged and a Bradford 
protein assay of the supernatant followed. The proteins 
were separated according to their molecular weight by 
a SDS-PAGE and transferred onto a PVDF membrane 
(Merck Millipore). Non-specific binding was blocked 
via a 1-h incubation of the membrane with 1× Casein 
Solution (Vector Laboratories, Burlingame, CA, USA). 
The primary antibodies anti-TAAR1, anti-ODC and anti-
β-actin (Clone AC-15, Mouse IgG, Sigma), diluted in a 
1:500 and 1:1000 Casein solution, respectively, were 
applied for 16 h at 4°C. After rinsing with 1× Casein 
solution, the membrane was incubated with biotinylated 
anti-mouse IgG antibody, respectively anti-rabbit IgG 
antibody and ABC-AmP reagent (both VECTASTAIN ABC-
AmP Kit for mouse IgG, Vector Laboratories) according 
to the manufacturer’s protocol. Staining was performed 
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with BCIP/NBT chromogenic substrate (Vectastain ABC-
AmP Kit, Vector Laboratories). Detection was carried out 
with Bio-Rad Universal Hood II (Bio-Rad Laboratories) 
and the values quantified using Bio-Rad Quantity One 
software (Bio-Rad Laboratories).
Double-immunofluorescence
To determine the cells that express TAAR1 and ODC in 
the decidua, double-immunofluorescence analysis with 
markers for extravillous trophoblast (EVT) and decidual 
stroma cells was performed. HLAG, which is a marker for 
EVT, was applied. Placental tissue of both ETP and RM 
groups were stained.
After tissue retrieval, tissue samples were fixed in 
3.7% formalin and embedded in paraffin. Formalin-
fixed paraffin-embedded sections (3 µm) were then 
deparaffinised in Roticlear (Carl Roth), rehydrated 
and blocked with 3% H2O2/methanol for 20 min for 
endogenous peroxidase activity. Rehydration of the 
slides was performed with an alcohol gradient up to 
distilled water. The slides were then placed in a pressure 
cooker containing sodium citrate (pH = 6.0). To prevent 
any non-specific binding of the primary antibodies, 
a blocking solution was applied for 15 min (Ultra 
V–Block, Thermo Scientific, Lab Vision, Lot: PBQ140925). 
Afterwards, incubation was performed with the primary 
antibodies overnight at 4°C (Table  2). The secondary 
antibodies Cy-2-labelled goat-anti-rabbit IgG, diluted 
1:100 (Dianova, Hamburg, Germany), Cy-3-labelled 
goat-anti-mouse IgG, diluted 1:500 (Dianova) and Cy-3-
labelled goat-anti-rabbit IgG, diluted 1:500 (Dianova) 
were applied on the slides. Finally, the slides were 
embedded in DAPI containing mounting buffer (Vector 
Laboratories, Vectashield H-1200). For the identification 
of TAAR1/HLAG expressing cells, the selected sections 
were additionally incubated with monoclonal HLAG-
FITC mouse IgG1 (Serotec, Bio-Rad) for 30 min, which 
was diluted 1:50. Afterwards, the slides were analysed 
with the fluorescent Axioskop photomicroscope (Zeiss). 
Images were taken with a digital Axiocam camera 
system (Zeiss).
Statistics
Data collection, processing and analysis of statistical 
data were performed with IBM SPSS Statistics for 
Windows, version 22.0. IBM Corp. All statistical tests 
were two-sided with a 5% significance level. Non-
parametric Mann–Whitney U tests were performed for 
comparison of central tendency. Wilcoxon signed-rank 
tests were performed for the statistical analysis of cell 
culture experiments. As causes for either spontaneous 
or RM differ, those two groups cannot be compared 
with each other. For ODC immunohistochemistry, a 
score developed from the percentage of low, middle and 
highly stained decidual cells in each sample was used. 
The formula is as follows: score = log10 (1 × percentage 
of low stained cells + 10 × percentage of middle intensity 
cells + 100 × percentage of highly stained cells).
Results
TAAR1 expression in the placenta
Via immunohistochemical analysis, a significant 
upregulation of TAAR1 protein expression could be 
detected in syncytiotrophoblasts, cytotrophoblasts, 
decidua and glands of RM in comparison to healthy 
controls (all P < 0.001) (Fig. 1). In spontaneous miscarriages, 
TAAR1 protein expression was also significantly 
increased in syncytiotrophoblasts, cytotrophoblasts, 
decidua and glands (decidua and glands: P < 0.001; 
syncytiotrophoblasts: P = 0.002) (Fig. 1).
Phosphorylated GSK3β expression in the placenta
Phosphorylated GSK3β protein (Y216) expression 
was significantly increased in RM in comparison 
to GSK3β protein expression in healthy controls in 
syncytiotrophoblasts (P = 0.031), cytotrophoblasts 
(P = 0.033) and in the decidua (P < 0.001). The difference 
between GSK3β expression in glands of RM compared to 
healthy controls was not significant (P = 0.286) (Fig.  2). 
There was no significant difference between GSK3β 
protein expression of spontaneous miscarriages and 
Table 2 Features of the antibodies used for double-immunofluoresence.
Primary antibodies Antibody type Company Dilution
TAAR1 Mouse IgG monoclonal Santa Cruz, sc-514311 1:300
TAAR1 Rabbit IgG polyclonal Abcam, ab65633, Lot: GR171220-3 1:800
ODC Mouse IgG polyclocal Novus Biologicals, SPM565, Lot: 4953-1XP160908 1:200
HLAG Mouse IgG1 monoklonal clone: MEM G/9 Serotec, MCA2044F, Lot: 300709 1:50
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Figure 1
TAAR1 expression in control placental tissue, spontaneous miscarriages and recurrent miscarriages. (A) Boxplot and scatterplot (all jittered) of TAAR1 
protein expression in syncytiotrophoblasts, (B) milder TAAR1 staining in syncytiotrophoblasts of control tissue, (C) stronger TAAR1 staining in 
syncytiotrophoblasts of recurrent miscarriages, (D) stronger TAAR1 staining in syncytiotrophoblasts of spontaneous miscarriages, (E) Boxplot and 
scatterplot of TAAR1 protein expression in decidua, (F) milder TAAR1 staining in decidua of control tissue, (G) stronger TAAR1 staining in decidua of RM, 
(H) stronger TAAR1 staining in decidua of SM, (I) Boxplot and scatterplot of TAAR1 protein expression in glands, (J) milder TAAR1 staining in glands of 
control tissue, (K) stronger TAAR1 staining in glands of RM, (L) stronger TAAR1 staining in glands of SM (all magnification ×25).
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Figure 2
GSK3β expression in control placental tissue, spontaneous miscarriages and recurrent miscarriages. (A) Boxplot and scatterplot (all jittered) of GSK3β 
protein expression in glands, (B) GSK3β staining in glands of control tissue, (C) GSK3β staining in glands of SM, (D) Boxplot and scatterplot of GSK3β 
protein expression in decidua, (E) milder GSK3β staining in decidua of control tissue, ×25 magnification, (F) stronger GSK3β staining in decidua of  
RM, ×25, (G) Boxplot and scatterplot of GSK3β protein expression in cytotrophoblasts, (H) GSK3β staining in cytotrophoblasts of control tissue, ×10,  
(I) GSK3β staining in cytotrophoblasts of RM, ×10, (J) Boxplot and scatterplot of GSK3β protein expression in syncytiotrophoblasts, (K) milder GSK3β 
staining in syncytiotrophoblasts of control tissue, ×25, (L) stronger GSK3β staining in syncytiotrophoblasts of RM, ×25.
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healthy controls in glands, decidua, syncytiotrophoblasts 
and cytotrophoblasts (Fig. 2).
ODC expression in the placenta
ODC expression in decidual tissue of controls and RM 
from 8th up to 13th week of gestation has been analysed 
and compared with each other (Fig.  3). In Fig.  3 it is 
apparent that ODC expression in decidual tissue of the 
controls and RM increases with gestational age (Fig. 4). 
There is a significant upregulation (P = 0.028) of ODC 
expression in RM in comparison to healthy controls for 
the subgroup of gestational weeks 8–10 (Fig. 4).
Figure 3
ODC expression in different pregnancy weeks. ODC 
expression has been analysed on the basis of a 
logarithmic scale with the following formula: log10 
(intensity 1 + 10 × intensity 2 + 100 × intensity 3). ODC 
expression in decidua of recurrent miscarriages and 
control tissue increases with gestational age.
Figure 4
ODC protein expression in decidual tissue of placentas from pregnancy weeks 8 until 10. (A) Boxplot and scatterplot (jittered) of ODC protein expression 
in decidua of control (gestational weeks 8–10) and miscarriages (weeks 8–10), showing a significant upregulation of ODC expression in recurrent 
miscarriages (P = 0.028). (B, D) ODC staining in control decidua in the 9th gestational week, ×10 (B) and ×25 (D). (C, E) ODC staining in decidua of 
recurrent miscarriages in the 9th gestational week, ×10 (C) and ×25 (E). (F) ODC staining in control decidua in the 10th gestational week, ×10.  
(G) ODC staining in decidua of recurrent miscarriages in the 10th gestational week, ×10.
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TAAR1 protein expression in BeWo trophoblast model 
cells after stimulation with T3, T1AM and RO5203548
Western blot
The stimulant T3 induced a significant upregulation of 
TAAR1 protein expression in BeWo cells at a concentration 
of 0.01 nM (P = 0.011) and 0.1 nM (P = 0.008) (Fig.  5). 
TAAR1 expression in BeWo cells was also upregulated after 
stimulation with 0.1 nM RO5203548 (P = 0.011) for 6 h 
(Fig.  5). At a lower concentration, 0.01 nM, RO5203548 
had no significant influence on TAAR1 expression 
(P = 0.859) (Fig. 5). The endogenous ligand T1AM induced 
a significant upregulation (P = 0.007) of TAAR1 expression 
at a concentration of 10 nM and after an incubation 
time of 6 h (Fig. 6).
ODC protein expression in BeWo trophoblast model 
cells after stimulation with T3
BeWo cells were stimulated with 0.01 nM and 0.1 nM T3 
for 48 h and ODC expression was analysed afterwards. 
Figure 7 shows a significantly increased ODC expression 
in BeWo cells after incubation with 0.01 nM T3 and 0.1 nM 
T3 (both P = 0.007) (Fig. 7).
Double-immunofluorescence
TAAR1 and HLAG
In placentas of electively terminated pregnancies (ETP) 
TAAR1-positive cells are stained in red (Fig.  8A) and 
HLAG-positive cells, which were identified as interstitial 
EVTs, are stained in green (Fig. 8B). Triple filter excitation 
of ETP shows the non-exclusive simultaneous expression 
of TAAR1 and HLAG in yellow (Fig. 8C), indicating that 
EVTs express TAAR1. ODC-positive cells are stained in red 
in control tissue (Fig.  8D), and an increased expression 
of ODC can be found in placentas of RM (Fig. 8G). Triple 
filter excitation of ETP shows a coexpression of ODC and 
HLAG visible in yellow (Fig. 8F). In placentas of RM, more 
cells stained in yellow can be detected compared to the 
controls, indicating an increased level of simultaneous 
expression of ODC and HLAG in RM (Fig. 8I).
Figure 5
Western blot analysis of TAAR1 expression after 
stimulation with T3 and RO5203548. (A) Bar graph 
diagram of TAAR1 expression after stimulation 
with 0.01 nM and 0.1 nM T3. (B) Bar graph 
diagram of TAAR1 expression after stimulation 
with 0.01 nM and 0.1 nM RO5203548. (C) Picture 
of Western blot membrane of BeWo cells where 
(D). BeWo cell control group. (E) BeWo cells 
stimulated with 0.01 nM RO5203548, (F) BeWo 
cells stimulated with 0.1 nM RO5203548.  
(G) BeWo cell control group, (H) BeWo cells 
stimulated with 0.01 nM T3, (I) BeWo cells 
stimulated with 0.1 nM T3.
Figure 6
Western blot analysis of TAAR1 expression after stimulation with T1AM. 
(A) Bar graph diagram of TAAR1 expression after stimulation with 10 nM 
T1AM showing a significant upregulation of TAAR1 expression (P = 0.007). 
(B) Picture of Western blot membrane of BeWo cells where (A). BeWo cell 
control group. (B) BeWo cells stimulated with 10 nM T1AM.
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ODC and HLAG
In control placental tissue of healthy pregnancies, an 
increased number of HLAG-positive cells, stained in green, 
can be detected (Fig. 8E), indicating an increased expression 
of EVT in controls in comparison to RM (Fig. 8H).
Discussion
In this study, the regulation of TAAR1, Phospho-GSK3β 
and ODC have been described in the placenta of healthy 
pregnancies and spontaneous as well as RM. A significant 
upregulation of TAAR1 in syncytio- and cytotrophoblasts, 
decidua and glands of spontaneous and RM may 
presumably be a sign for an increased decarboxylation 
of thyroid hormones in miscarriages. A lack of thyroid 
hormones during pregnancy may possibly induce an 
upregulation of TAAR1 expression, which denotes a 
metabolism of thyroid hormones. An excess of thyroid 
hormones may lead to an increase in decarboxylation 
of thyroid hormones, which can consequently have a 
negative effect on the pregnancy.
An interaction between TAAR1 and D2R has recently 
been described (6). Harmeier and colleagues suggest 
that a heterodimerisation of TAAR1 and D2R elevates 
the recruitment of βArr2 to TAAR1 and activates Akt, 
which consequently leads to an inhibition of GSK3β 
via an alternative pathway (6). Enhanced GSK3β 
phosphorylation indicates a silencing of the downstream 
signalling cascade (36, 37). In our study, we discovered 
enhanced expression of phosphorylated GSK3β (pGSK3β) 
expression in syncytiotrophoblasts, cytotrophoblasts and 
the decidua of RM in comparison to healthy controls 
and thereby a concomitant pGSK3β expression with 
TAAR1. An increase in pGSK3β expression leads to an 
inhibition of unphosphorylated GSK3β and consequently 
to an activation of the Wnt signalling. In a current 
study, we also investigated a reduced D2R expression 
in syncytiotrophoblasts and cytotrophoblasts of RM 
in comparison to trophoblasts of healthy controls (in 
revision at JCEM). These findings are in line with the 
results of Espinoza and coworkers, who detected a 
negative correlation between TAAR1 and D2R in the 
striatum of TAAR1-KO-mice, where D2 dopamine 
receptors are overexpressed and thereby selectively 
activate the G-protein-independent AKT/GSK3 signalling 
pathway (24). In contrast, Harmeier and coworkers found 
a concomitant increase of TAAR1 and D2R expression in 
the neurone cell line HEK293 (6). This difference might 
be due to the variability of TAAR1 and D2R expression in 
different cell lines and tissue.
One further aim of the study included the 
identification of ligands that have the ability to upregulate 
TAAR1 expression in trophoblast model cells and could 
thereby be responsible for the induction of miscarriages. 
Triiodothyronine, also known as T3, at a concentration of 
0.01 nM and 0.1 nM induced a significant upregulation 
of TAAR1 expression in BeWo trophoblast model cells. 
The ligand RO5203548 significantly increased TAAR1 
expression in BeWo and JEG-3 cells. RO5203548 has been 
described as a partial agonist and highly selective for 
TAAR1 in dopaminergic neurons (15). Partial agonists can 
either act as an agonist or an antagonist depending on the 
intrinsic activity of the receptor (15). Endogenous ligands, 
such as T1AM, have a high affinity for TAAR1 (13, 18). In 
our study, 10 nM T1AM induced a significant upregulation 
of TAAR1 expression after an incubation time of 6 h. 
We are aware of the fact that TAAR1 has an intron-less 
sequence. For that reason, we performed intense genomic 
DNA digestion to avoid that TAAR1 RNA is contaminated 
Figure 7
Western blot of ODC expression. (A) Boxplot analysis of ODC expression 
in BeWo cells after incubation with T3. 0.01 nM and 0.1 nM T3 induce a 
significant upregulation of ODC protein expression (P = 0.007). (B) Picture 
of Western blot membrane of BeWo cells where (A) and (B) BeWo cell 
control group. (B) and (E) BeWo cells stimulated with 0.01 nM T3 for 24 h. 
(C) and (F) BeWo cells stimulated with 0.1 nM T3 for 24 h.
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with genomic DNA. We used commercially TAAR1 
primers from ‘Applied Biosystems by Thermo Fisher’. 
The policy of the company forbids to publish the primer 
sequences but the company guarantees the specificity 
of the sequences. An upregulation of TAAR1 is induced 
through the transformation of T3 into T1AM. We could 
detect that 0.01 nM and 0.1 nM T3 induced a significant 
upregulation of ODC expression in BeWo cells via 
Western blot analysis. An increased expression of ODC 
after stimulation with T3 suggests that thyroid hormone 
derivates are present during miscarriages. Transformation 
of thyroid hormones into endogenous amines may 
therefore partly be carried out by the ODC. In our study, 
all patients with RM had normal thyroid hormone levels. 
Individuals with hypothyroidism and hyperthyroidism 
and patients with TPO antibody positivity were excluded 
from the study as those pathologies can influence 
miscarriage rates. We presume that patients with normal 
thyroid hormonal levels possibly have a deficiency of 
T3 during pregnancy induced through the ODC. In a 
former study, we found that patients with spontaneous 
and RM have reduced expression of THR (5). A reduced 
level of THR during pregnancy may rather be due to an 
enhanced transformation of thyroid hormones into their 
derivate T1AM than to a decrease in thyroid hormone 
synthesis. One possible approach could therefore be a 
prophylactic substitution of l-thyroxin to patients with 
RM, independent of their TSH and thyroid hormone 
levels. A further possibility to reduce the transformation 
of T3 into T1AM would be an inhibition of the ODC.
In conclusion, we found enhanced placental TAAR1 
and pGSK3β expression in RM, which consequently 
leads to an inhibition of GSK3β and activation of the 
Wnt-signalling pathway. TAAR1 seems to be an inductor 
of the wnt-signalling pathway, and could play role in 
the embryonal development. Inhibition of GSK3β, as 
Figure 8
Double-immunofluorescence of TAAR1 and ODC. (A) Red stained TAAR1 expression in elective terminations of pregnancy. (B) Green stained HLAG 
expression in decidua of ETP placenta. (C) Coexpression of TAAR1 and HLAG in ETP visible in yellow. (D) Red stained ODC expression in decidua of ETP 
placenta. (E) Green stained HLAG expression in decidua of ETP placenta. (F) Double staining of both ODC and HLAG. A double expression is visible in 
yellow. (G) Red stained ODC expression in decidua of RM placenta. (H) Green stained HLAG expression in decidua of RM placenta. (I) Double staining of 
both ODC and HLAG. A double expression is visible in yellow; (all magnification ×40).
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observed in the neurological system through TAAR1, 
could also be detected in RM, indicating a TAAR1-
dependent regulation of GSK3β in RM. Using endogenous 
ligands, we demonstrated a T3, RO5203548 and T1AM-
dependent upregulation of TAAR1 in trophoblast tumour 
cells. Aims of future studies include investigation of the 
functional interaction between TAAR1, ODC, GSK3β and 
the Wnt-signalling pathway in placentas of miscarriages. 
Future experiments should elucidate the role of βArr2 in 
the signalling cascade in miscarriages. βArr2 is known 
to dephosphorylate Akt and thereby activate GSK3β (6). 
In vivo experiments with a knockout or knockdown of 
TAAR1 through antisense or siRNA technologies should 
be considered. TAAR1 may represent a novel target for 
the treatment of miscarriages. Further studies are required 
to analyse the signalling pathways of the endogenous 
ligands of TAAR1 and to possibly re-examine thyroid 
hormone signalling (38).
Supplementary data
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